Maratos-Flier, B
Biomarker development for intraductal papillary mucinous neoplasms using multiple reaction monitoring mass spectrometry
The FDA noted that such claims violate sections of the Federal Food, Drug, and Cosmetic Act
Consult your healthcare provider to determine the best option for your situation
Although the enrichment of L-cells by pharmacological agents can be a novel approach for improving insulin secretion, glucose tolerance and the treatment of T2DM, more research for the specific differentiation of L-cells and the translation of in vitro and animal data to humans, are needed for the success of this approach
The right choice hinges on your starting weight, your other conditions, your insurance, what side effects you can tolerate, and what you actually want out of treatment